MUMBAI, India and NAPLES, Fla. — Global pharmaceutical leader Lupin Limited today announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Farxiga® for the indications in the approved labeling.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
*Safe Harbor Statement
Farxiga is a registered trademark of AstraZeneca AB.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
